SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Vanguard " 38 found 🔀 AI-powered Shuffle
Patient-Owned Health Data Model Reduces Clinical Trial Recruitment Redundancy
Patient-owned health data model reduces clinical trial recruitment redundancy by enabling persistent consent and longitudinal data sharing across studies.
Nirvana is set to receive this year's VMAs Video Vanguard Award. Could someone like Kurt Cobain still become a star today?
Cobain seemed to resist and even resent his own success. It was a struggle that played out on MTV.
Is Vanguard Health Care Index Admiral (VHCIX) a Strong Mutual Fund Pick Right Now?
Mutual Fund Report for VHCIX
AB Science’s “Calendar Update” Is a GCP Inspection Disclosure in Disguise
AB Science buried a five-inspector "for cause" GCP inspection inside a financial calendar update. Masitinib's ALS trial and three terminated studies deserve a…
Benchmark Scores Don’t Break. Clinical Reality Does. The Health AI Readiness Illusion.
Nature Medicine's frontier AI evaluation exposes a dangerous gap: models acing medical benchmarks collapse under adversarial pressure, and the FDA has no…
Vanguard Reports 0 Shares of Golden Entertainment
Amendment No.2 shows The Vanguard Group disaggregated subsidiaries and reports 0 shares (0%) of Golden Entertainment common stock, signed 03/27/2026.
The Liquid Biopsy That Found Pancreatic Cancer Early Has a Bigger Regulatory Problem Than Its Science
PANXEON detects stage 1-2 pancreatic cancer with 87% sensitivity, but FDA's companion diagnostic pathway may be the bigger obstacle to clinical adoption.
The New Fabio Is Claude
The romance industry, always at the vanguard of technological change, is rapidly adapting to A.I. Not everyone is on board.
A New Habitat at the Bottom of the Ocean Is Waiting for Its First Aquanauts
Four scientists could soon live and work beneath the Florida Keys for days.
Florida High School Football: Ocala Vanguard releases slate
Florida high school football schedules for the 2026 season are coming out one-by-one out of every state around the country and one region that is always a breeding ground for college prospects is over in the North Central Florida region, with a number of squads finalizing their fall slates. [ $19.99 gets you a FULL […]
Nature Medicine Just Published the AI Mental Health Audit Framework the FDA Hasn’t Written Yet
Nature Medicine's clinically validated AI chatbot audit framework arrives as FDA still lacks generative AI mental health approval standards—here's what trial…
Why this Stanford psychiatrist thinks diet can influence serious mental health disorders
Shebani Sethi is at the vanguard of metabolic psychiatry, a field that investigates the link between diet and serious mental health disorders.
Lilly’s $2.8 Billion Bet on Psychedelics Buys Science That Conventional Trial Infrastructure May Not Be Able to Run
Eli Lilly acquires AtaiBeckley for $2.8B, but the FDA's final psychedelic trial guidance reveals an operational crisis Big Pharma hasn't priced in.
Everyday Injustice Podcast Episode 337: Marc Bookman Examines the Death Penalty’s Politics, Failures and Enduring Appeal
Marc Bookman, legal director of the Atlantic Center for Capital Representation, recently discussed capital punishment on Episode 337 of 'Everyday Injustice.' Bookman challenged the perception of a national death penalty resurgence, asserting its continued application is increasingly confined to a limited number of states. He also critiqued public opinion polling on capital punishment, specifically a Pew poll, for failing to present alternatives such as life without parole. Additionally, Bookman previewed his forthcoming novel, 'Albert's Time,' which explores the ethical dimensions of capital punishment by confronting the execution of an undeniably guilty individual.
An army of paid creators is carpeting the web with political content
Functioning more like birdshot than a single bullet, these high-volume social media campaigns represent the new vanguard of modern political influence, saturating the internet with a topic.
Vanguard Settles on ESG — BlackRock and State Street Fight On
Vanguard’s settlement in Texas v. BlackRock marks a historic victory for the anti-ESG movement. But BlackRock and State Street are still fighting for what remains of sustainability stewardship in the US.
Some Valorant players need to update their PC BIOS to keep anti-cheat software happy
BIOS checks will only affect a limited subset of Valorant players for now.
States Take Uneven Approach to Convictions Built on ‘Junk Science,’ State Court Report Examines
States are implementing divergent legal frameworks regarding criminal convictions predicated on forensic evidence subsequently identified as 'junk science,' resulting in varied outcomes for incarcerated individuals seeking relief, according to a recent analysis by State Court Report.
Valorant's new Vanguard update seems to be bricking cheaters' PCs. Riot's response? "Congrats on your $6k paperweights"
Riot's latest Vanguard update is bricking cheaters' PCs, to the point where they have to do full OS reinstalls, and it's not sorry. At all.
We can create the future of science right now
Paul Litvak is the founder and Executive Director of the Robyn Dawes Institute and a Visiting Scholar at UC Berkeley. He has a PhD in Behavioral Decision Research from Carnegie Mellon where he studied emotions and the sunk cost bias. Over 15 years in industry, he solved a wide range of challenging technical problems. At Meta he created models optimizing the ad review process. At Google he ran experiments to measure social influence. At Airbnb, he was a product manager leading machine learning teams optimizing search ranking and price suggestions. He also co-founded and led product at Rhythmic Health, a venture-backed biosensing startup, creating an accurate low cost system using a color changing strip and a smart phone to measure salivary lactate. The bottleneck At this point, it is uncontroversial to say that science needs to stop using the PDF article as the unit of knowledge and currency. The unbearable slowness of scientific publishing, the profit motive and margins: I’m not saying anything new. The PDF also sucks because it’s hard to extract structured information, which makes it hard to do evidence synthesis. As a result, we do much less evidence synthesis than is needed. And evidence synthesis ultimately undergirds most policy and medical decision-making. I can see second-by-second real-time odds for any sporting or newsworthy event, but a school board can’t see the best evidence on whether their 8th graders should be taught algebra. As a society, we don’t treat this as an important problem. Again, not controversial. Not only is the problem well understood, but the solution has already been laid out. What we need is AI-assisted living evidence synthesis - (1) an open knowledge graph of atomic claims, (2) claims linked to evidence, (3) assessment and synthesis of each piece of evidence, and (4) continuous updating with new data. What few realize (yet) is that the technical capacity to build this vision for a significant portion of science already exists. Not only that, scientists and startup teams are already building many of these components. I know this because I’ve been surveying the space and talking to many of the builders. There are some missing pieces: for example, evaluations of how well some of the components work. But at this point, most of what’s missing is a fully end-to-end working integration of all of these parts. In the rest of this essay, I’m going to lay out all the parts of a working living evidence layer for science and who is working on them, and propose concrete next steps for building this system. What’s now possible The diagram above outlines the components of a living evidence synthesis platform, including some of the teams working on each component1. Scientific PDFs are processed into claims with associated evidence. The evidence is subjected to a forensic audit, methodological evaluation and robustness and reproducibility checks. Finally it’s given a weight in a continuously updating synthesis. What follows is a description and status of each component and a few of the teams working on them. Document understanding The first thing you need to be able to do is turn an article into structured data. Mostly that means parsing PDFs. There are often multicolumn layouts that confuse non-specialized PDF to text processing libraries. For scientific papers, there is the added complexity of parsing formulas and tables and figures. This is a really hot area - there are startups offering APIs, and it seems like a new open source package gets posted to Github every few weeks. What follows isn’t exhaustive. A package called GROBID was the state of the art for a while, they didn’t update their package for nearly two years until very recently. In the meantime reducto.ai released an AI powered PDF extraction API, PaddleOCR became popular, IBM released a model called Docling, and both Mistral and Gemini created models and libraries. I also know of at least one other well-funded psychology research group working on a paper parser. By contrast, there are few open evals in this space, with no extensive evals for complex table comprehension in particular. Nonetheless, I’m confident this will be a solved problem soon, given the combination of LLM advances and developer interest. Hypothesis level extraction There has been increasing interest in comprehending the extracted text of papers and linking information to evidence for each hypothesis. A lot of work has already been done. Trialstreamer (Marshall et al. 2020) and RobotReviewer LIVE (Marshall et al. 2023) demonstrated automated extraction of trial population, intervention, and outcome at scale on clinical RCTs. PaperQA2 (Skarlinski et al. 2024) and Ai2 ScholarQA (2024) extended this to retrieval-augmented question answering with citation grounding. Elicit, Consensus, and SciSpace operationalized claim-level extraction for end users. OpenEval (Booeshaghi et al. 2026) is the most recent and most ambitious: 1.96 million atomic claims extracted from 16,087 eLife manuscripts using Claude Sonnet 4.5, grouped into ~299,000 results, with LLM evaluations showing 81% agreement with human peer review on a 2,487-paper subset. None of these solutions link claims to test-statistics, as you would need to evaluate randomized controlled trials. This is why I built the evidence.guide API - to extract hypotheses and associated test statistics from behavioral science papers. The best public eval of this kind of extraction I’m aware of comes from the recent SCORE project - they had humans code thousands of psychology papers to extract their claims by hand. It would be extremely helpful to the world if all scientific PDFs were available as structured open data. I’ve been working to make this happen, both directly at Berkeley and through coordination with large entities I can’t yet speak of; as hard as it is to do, I think it’s possible2. Forensic audit A lot of work has been done on forensic audit, but some gaps remain. Of course, for biology papers that rely on images for evidence, there are a variety of tools (notably Proofig and ImageTwin) to spot anomalies. These are still well short of what sleuths like Elizabeth Bik can do on her own, but these tools are constant companions among fraud analysts. There’s someone working on auditing Excel files for anomalies, and a number of teams are automating numerical checks like GRIM and SPRITE, including Scrutiny project, the INSPECT-SR team as well as statcheck. The regcheck team is building a way to use AI to compare preregistrations to analyses in papers, to ensure there aren’t significant deviations. Nonetheless, there are many other kinds of anomalies to screen for, both public and less publicly known. And there are no formal evals for anomaly detection that I’m aware of. Still, there’s a lot to draw from in this space and I’m pretty certain we will be able to scan papers for most kinds of obvious anomalies in the near future. Methodological review This area has been white hot, though I fear for many of the startups in this space, because this capability may become commoditized. There are at least six different AI peer review companies, including Refine.ink, Reviewer3, ReviewerZero.ai, Q.E.D. Science, Paper Wizard, and Isitcredible. Coarse (a pun on refine) was also recently created as an open source alternative. These systems provide qualitative feedback on the content of papers, spotting methodological weaknesses and mathematical errors. They seem to work pretty well, and many academics report bitterly that they exceed the average quality of typical peer reviewers. But there are few evals here either. What evals exist so far involve using LLM-as-judge (circularity problems abound) or comparing against human reviews of questionable quality. What you’d ideally want is an eval that measures capturing known errors in papers3. Reproducibility and robustness Another active area has been using AI agents to automate computational reproducibility4 and robustness5 checks in papers that report numerical results. For more recent papers where data and code are available, AI agents can see whether they can re-run the analyses and produce the numbers reported in the published paper. In addition to a handful of individual academics who have been experimenting using Claude Code for this, the Institute for Replication is a leading group working on building an end to end system. The evals related to this problem are the most mature, with CORE-Bench (Siegel, Kapoor, Narayanan 2024) and PaperBench (OpenAI 2025) available to benchmark agents on this task. There is also work on getting AI agents to test alternative ways of analyzing the data to ensure the results are robust to small analytic design choices. Synthesis This is the most underdeveloped area where significant investment is required. Although some automated evidence synthesis systems exist — for example, otto-sr is building an AI agent to write systematic reviews — none of these incorporate the full range of paper level signals to weight evidence appropriately. Nor is there anything like an eval or a gold standard for a good systematic review. Arguably Cochrane reviews are the closest we have to gold standard human systematic reviews, though I’ve heard academics in the know complain about their uneven quality. A key question for a synthesis platform is how to weight anomalies and methodological issues in assessing the quality of a piece of evidence. This is an unsolved problem and one I’m very keen to work on. Continuous updating There are many pieces of basic infrastructure available for monitoring for new research and initiating updates. OpenAlex is the current open citation graph. Retraction Watch integrated into Crossref in October 2023. Scite tracks how citations support, contrast, or mention prior claims. The Living Evidence Network demonstrated continuous-update workflows in clinical guidelines. Engineering this is a relatively straightforward task. When you look over this technical architecture and all the progress being made, it’s hard not to be optimistic that a living guide to scientific evidence will be built. The stakeholders are ready The social infrastructure for this is starting to coalesce — it’s not just a pie in the sky academic exercise to imagine this coming into existence. Institutions like the Center for Open Science, the Institute for Replication, the INSPECT-SR, the Living Evidence Network and more are all working on scaling work to improve research quality. Funders are also aligned. The Sloan Foundation has funded living evidence work through COS. Coefficient Giving supports the Institute for Replication and COS. The Astera Institute and the Institute for Progress have shown interest in this space. NIH has established an Office for Replication and Reproducibility. Although there are (very unfortunately) serious headwinds in science funding generally, there is an active group of funders interested in metascience. A brief word about what I’ve been doing at RDI. First, as a Visiting Scholar at Berkeley I’ve been actively figuring out how a non-profit and a public university can conduct and make public the results of large-scale academic article data mining. With some of the money I raised from donors, I commissioned a legal analysis of recent case law and publisher text data mining (TDM) agreements in order to understand whether a massive open data mining of academic articles is possible (with caveats, it is). I’ve also been working to bring together stakeholders in this space, and identify gaps. I’ve also been doing some software development in this space, with more to come. A pilot proposal The assumption undergirding all of this is that an AI, given all this information, would make the right judgment about a scientific claim with lots of conflicting evidence, weighing all the factors appropriately. That’s the hypothesis we need to test. Randomized control trial research is the best place to focus on first. RCTs are used to make many of the important decisions in society - from medical trials to public policy changes. And they use a relatively uniform set of inferential statistics with lots of known and available diagnostics. Behavioral science experiments, within the broader realm of RCTs, should be first used as a testbed whose results can be generalized. Because behavioral science is at the vanguard of open science practices, replications abound (there are thousands of them) to serve as ground truth training data. Key Hypothesis Therefore the pilot would test, in behavioral RCTs that have been replicated, whether the quality of evidence for a claim can be used to accurately predict whether that claim will replicate. Secondary Hypotheses Compared to claims that replicated, non-replicated claims demonstrate a greater share of forensic anomalies in their source literatures. Hypothesis level claim and statistic extraction is accurate enough to scale living evidence without onerous human review costs. Replication prediction is more accurate than prediction markets6 or journal prestige. If all the different quality signals we gather do accurately predict which studies will replicate, then we can use that model to score evidence to power the living evidence layer. Why this is informative regardless of outcome If the pilot succeeds, the architecture extends to medical RCTs (where Living Evidence already operates and integration is mostly about claim representation), then to slices of basic biology with stable replication structure. If it fails, the field learns which quality signals are load-bearing and which ones metascience has oversold. Either result is a contribution to knowing what the literature supports. Implications for funders Because this burgeoning ecosystem of builders already exists, a well-informed philanthropic or government funder could play a crucial catalyzing role in bringing this future about. They could play at least three roles: creating open structured datasets, publishing open benchmarks and incentivizing the solving of key technical challenges. First, open archives of papers that the government maintains, like PubMed, could be turned into structured data amenable to large scale metascience and claim aggregation. I know the US government already has an interest in doing this, though some key open questions remain unanswered. How do you determine the best models and systems for accurately extracting information from papers? How can you establish a robust way to allow researchers to flag errors and correct them? And finally, how do you create a legal regime in working with publishers to maximize the scope of available papers? For the latter, a university or a private philanthropy may be better positioned to make structured data publicly available under journal subscription terms or fair use. Philanthropists or government funders could also coordinate to create or commission benchmarks that evaluate whether important problems have been solved. For example, an open benchmark for claim extraction from a range of different scientific article types would be extremely helpful. Ensuring the underlying data are accurate is vital for creating these evaluations. I’ve discussed opportunistically using various human-created datasets for this purpose, but a consistent problem is that errors in human data make it difficult for them to serve as a gold standard. Finally, with structured data and benchmarks available, the government or private philanthropy could use them to incentivize groups to develop machine learning systems that meet these benchmarks. Prizes are one potentially valuable tool for this. For example, you could establish a prize for a system that accurately updates a living meta-analysis for a small set of claims. Prizes are particularly useful as signals of problem importance, and can help create vibrant ecosystems of public and private research—see, for example the role the government played in kickstarting the current work on nuclear fusion. Conclusion The drawbacks of the current scientific publishing system are known. Scientists agree, metascientists agree, philanthropists agree: the published PDF plus citation graph isn’t the right substrate for maintaining a representation of the evidence base in science. The pieces needed to build the alternative either already exist or are rapidly taking shape. The community is forming around exactly this problem, with concrete partnerships and shared infrastructure. A pilot should start on behavioral science RCTs because that’s the slice of empirical science most amenable to legibility, where replication ground truth is richest, and where the failure modes are best documented. What’s been missing is the galvanizing mission to assemble these pieces into something that works. That’s what I’m proposing to build. *** 1 I have a broader field map that I’ll release publicly soon. This is me, building in public! 2 If this is something that you are excited about, please reach out and talk to me. 3 More on this very soon too! 4 This tests whether, given the code and the data, you can get the same statistics as reported in the published paper. 5 This tests whether the results are the same as a paper’s given alternative analytical decisions in conducting the analysis (like outlier omission). Closely related is the idea of a “multiverse” where you come up with many different ways of answering the same underlying research question with the same data, and test whether the results hold in all those alternative methods. There’s been work on the latter as well. 6 Some of the replications, e.g. those from the SCORE project, had paired the experiments with forecasts from prediction markets. So we get to look at this for free.
Gamer Buys Used Ryzen 7 5800X3D, Gets Locked Out of Valorant Because Previous Owner Cheated
A buyer of a Ryzen 7 5800X3D found it banned by Riot's Vanguard anti-cheat, impacting their entire system and highlighting risks in the second-hand PC market.
Just in: Ex-Science minister Uche Nnaji arrested at Abuja Airport
Former Minister of Science and Technology, Uche Nnaji, was on Wednesday arrested at the Nnamdi Azikiwe International Airport, Abuja, shortly after arriving from Enugu aboard a chartered flight.
Nirvana is awarded the 2026 Video Vanguard Award: What to know about the MTV VMAs
Nirvana was awarded the 2026 Video Vanguard Award at the starry 2026 MTV Video Music Awards. Madonna opened the show and was joined by her recent collaborators Sabrina Carpenter and
David Sinclair Launches Lifespan Media Platform for Longevity Science
David Sinclair launches Lifespan media platform to improve public understanding of longevity science research and clinical trials.
Apotex Gets Health Canada Approval for Generic Semaglutide
Apotex receives Health Canada approval for generic semaglutide injection, matching all commercial formats of Novo Nordisk's Ozempic for type 2 diabetes treatmen
Did DOJ Settlement and Strong Ticket Demand Just Shift Live Nation Entertainment's (LYV) Investment Narrative?
Live Nation Entertainment recently outlined continued strong global concert demand, pricing power and a favorable Department of Justice settlement that avoided a Ticketmaster divestiture, while also confirming past management presentations at MoffettNathanson and J.P. Morgan investor conferences, both of which were webcast to investors. These developments, alongside Vanguard holding over 12.04 million shares and modest insider selling, spotlight how regulatory outcomes and investor...
Xiaomi 17 Ultra Leads And Samsung To Follow With A 10 Percent Price Hike For Its Galaxy S26 And Z Fold/Flip 8 Series
Xiaomi is currently acting as a vanguard by hiking the launch price of the Xiaomi 17 Ultra by 10 percent, with Samsung and Apple to follow.
Capricor’s Duchenne AdCom Didn’t Fail on Science. It Failed on Statistics.
FDA's CTGTAC voted 9-3 against Capricor's deramiocel on July 30, 2026. The science wasn't the problem. The statistical methodology was — and the FDA let it get…
Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up?
Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit.
Riot now lets you enable its anti-cheat when you want to
You’ll be able to turn on Vanguard just while you’re playing.
Warhammer 40K: New Vanguard Veterans From Armageddon Box Revealed
The new Armageddon box is coming with a bunch of updated and new miniatures. Today we get a look at the new Vanguard Veterans!
Signant Health, Lothar Medical Plan Integrated Respiratory Trial Device
Signant Health and Lothar Medical plan integrated respiratory trial device combining spirometry, oscillometry, and FeNO measurement into a single platform.
Federal Rule of Evidence 702 Could Help End Junk Science in Courtrooms
Following the exoneration of Jimmie "Chris" Duncan, legal experts have urged states to adopt Federal Rule of Evidence 702 standards, a measure intended to prevent wrongful convictions stemming from unreliable forensic testimony, commonly termed "junk science."
Lagos school emerges winner of 10th Edition of Tolaram Science Challenge
By Efe Onodjae Iwerekun Community Senior High School, Ibeju-Lekki, has emerged the winner of the 10th edition of Tolaram Science Challenge (TSC), marking their third consecutive win. The school triumphed over Magbon-Alade Senior Grammar School in a keenly contested grand finale of the competition. The Tolaram Science Challenge, sponsored by Lagos Free Zone, is an annual […]
The Blood-Brain Barrier Has Been Breached. Is Clinical Trial Science Ready?
FDA's March 2026 approval of AVLAYAH marks the first BBB-crossing biologic — but CNS trial design, PK monitoring, and safety frameworks haven't caught up.
Riot Games Says It 'Would Not and Cannot' Use Vanguard Anti-Cheat to Brick PCs After Rumors Spread
"This means the cheat device won’t work with our games, but your PC isn’t 'bricked.'"
Eric Jones Calls for a New Politics to Fight Corruption, Corporate Power and Rising Costs
Democratic challenger Eric Jones has initiated a campaign for Congress against longtime incumbent Representative Mike Thompson, with his platform emphasizing political reform, the mitigation of corporate influence, and the amelioration of economic inequality.